Target Blood Glucose for Diabetic Patients Admitted to Ward with Acute Illness
For diabetic patients admitted to the ward (non-ICU) with acute illness, target a random blood glucose of less than 10.0 mmol/L (ideally 7.8-10.0 mmol/L), initiating treatment when glucose persistently exceeds 10.0 mmol/L on two occasions within 24 hours. 1
Algorithmic Approach to Glycemic Targets
For Non-Critically Ill Ward Patients (Your Scenario):
Start insulin therapy when:
- Random blood glucose ≥10.0 mmol/L confirmed on two separate measurements within 24 hours 1
Target range once treatment initiated:
The 2024 ADA Standards of Care 1 provides the most recent high-quality guideline evidence, recommending initiation of therapy at ≥10.0 mmol/L (180 mg/dL) for non-ICU patients, with a target of 7.8-10.0 mmol/L once treatment begins. This represents a consensus position that balances efficacy against hypoglycemia risk.
For Critically Ill Patients (ICU):
If the patient deteriorates and requires ICU admission:
- Target: 7.8-10.0 mmol/L (140-180 mg/dL) 1
- More stringent targets of 6.1-7.8 mmol/L may be considered for select patients (e.g., post-cardiac surgery) if achievable without significant hypoglycemia 2, 1
Key Evidence Considerations
The NICE-SUGAR trial fundamentally changed glycemic management by demonstrating that intensive glucose control (targeting 4.4-6.1 mmol/L) increased mortality compared to moderate control (targeting 10.0 mmol/L or less) 2, 1. This landmark study showed 10-15 fold higher hypoglycemia rates with aggressive targets, directly contributing to worse outcomes.
The UK JBDS guidelines suggest a slightly wider acceptable range of 4.0-12.0 mmol/L, though the lower limit of 4.0 mmol/L is controversial due to hypoglycemia risk 2. In real-world ward settings, the more conservative ADA target of 7.8-10.0 mmol/L is safer and more practical.
Critical Pitfalls to Avoid
Avoid aggressive glucose lowering (<7.8 mmol/L) in acute illness:
- Increases hypoglycemia risk 4-6 fold compared to conservative management 2
- No mortality benefit demonstrated 1
- Particularly dangerous in patients with poor oral intake, renal impairment, or age >65 years 2
Higher targets may be acceptable (up to 11.1 mmol/L) in:
- Terminally ill patients
- Severe comorbidities
- Settings with limited glucose monitoring capability 2
Monitoring Frequency
- If eating: Check before meals
- If NPO (nil by mouth): Check every 4-6 hours 1
This evidence-based approach prioritizes patient safety by avoiding both the complications of severe hyperglycemia and the substantial mortality risk associated with iatrogenic hypoglycemia in acutely ill patients.